Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Paradigm Biopharmaceuticals ( (AU:PAR) ) just unveiled an update.
Paradigm Biopharmaceuticals Limited announced a proposed issue of 27 million convertible notes as part of a new placement. This strategic move is aimed at enhancing the company’s financial flexibility and supporting its ongoing initiatives in the biopharmaceutical sector, potentially impacting its market position and offering opportunities for stakeholders.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on developing and commercializing therapies for treating diseases. The company is primarily involved in creating innovative solutions for unmet medical needs, with a market focus on advancing healthcare through novel biotechnological applications.
Average Trading Volume: 872,229
Technical Sentiment Signal: Sell
Current Market Cap: A$124.6M
For an in-depth examination of PAR stock, go to TipRanks’ Overview page.